AusCann Joint Venture commences first cultivation

Company News

by Anna Napoli

Medical cannabis company, AusCann (ASX:AC8) says its DayaCann joint venture is set to kick off its third party cannabis cultivation with Canadian medical cannabis company Khiron Life Sciences.

AusCann announced a Memorandum of Understanding with the companies last year to collaborate on the development of medicinal cannabis products and market in Chile.

The MoU contemplates a collaboration through which AusCann's Chilean joint venture, DayaCann and Khiron can offer new alternatives of medical cannabis to patients in Chile, in addition to those currently provided.

DayaCann is now preparing for cultivation of cannabis plant material to be used for patients and clinical trials.

Dayacann is the only company in Chile to hold a medical cannabis production license.

Shares in AusCann (ASX:AC8) are trading 1.42 per cent higher at 71 cents.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.